Hikma Pharmaceuticals PLC 2013 AR2
The report highlights Hikma Pharmaceuticals' strong financial and operational performance in 2013, with revenue increasing by 23% to $1,365 million. The company expanded its global footprint by entering into a joint venture in Ethiopia and completing an acquisition in Egypt. In sustainability, Hikma focused on addressing major health issues, raising patient and doctor awareness, and supporting local communities. The company also measured its carbon footprint, reporting Scope 1 emissions of 16,817 tCO2e and Scope 2 emissions of 49,779 tCO2.
Company: Hikma Pharmaceuticals PLC
Sector: Manufacturing
Country: United Kingdom
Year: 2013
Type: AR2
Pages: 180
Back to company
Hikma Pharmaceuticals PLC
Annual Report
The report highlights Hikma Pharmaceuticals' strong financial and operational performance in 2013, with revenue increasing by 23% to $1,365 million. The company expanded its global footprint by entering into a joint venture in Ethiopia and completing an acquisition in Egypt. In sustainability, Hikma focused on addressing major health issues, raising patient and doctor awareness, and supporting local communities. The company also measured its carbon footprint, reporting Scope 1 emissions of 16,817 tCO2e and Scope 2 emissions of 49,779 tCO2.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2013
Reporting Period
Jan 1, 2013 - Dec 31, 2013
Fiscal Year
2013
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Women on Board
Women in Management
Employees